Measles vaccination as developed by Enders and others has been proven safe and efficacious.1,2 Modification of clinical response to attenuated measles infection by simultaneous administration of immune globulin has become the most widely used method in the United States.3-9 However, even in this country, where natural exposure to measles virus is more apt to take place after age 2, the early protection of infants remains a problem. It is of greater importance to areas of the world where measles characteristically occurs before the second birthday.10-12
An alternative method of modifying attenuated measles vaccine has been prior inoculation of inactivated vaccine in 1, 2, or 3 doses.9,13-15 Feldman16 and Karelitz17 have reported that infants who had received prior inactivated vaccine, when challenged with mild measles or live attenuated measles virus vaccine exhibited antibody production with minimal reaction. It appeared that this might be worthy of
ALEXANDER ER, BANSMER CAM, HARRIS ES, GILES B, SPARKS MJ. Measles Vaccination In Infants: Use of Killed-Live Combinations. Am J Dis Child. 1964;108(5):470–478. doi:10.1001/archpedi.1964.02090010472005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: